eGFR and Medicines: Metformin, Gabapentin, and the Right Kidney Estimate

Kidney function can affect how a medicine is cleared, but a CKD stage is not a dosing instruction. The drug, indication, formulation, kidney-function method, body size, dialysis status, and other clinical information all matter. A table that assigns “usual,” “reduced,” or “avoid” to every medicine using the same eGFR bands can give misleading advice.

This guide explains how to prepare a medication review. Use our eGFR calculator for education; a clinician or pharmacist must select the appropriate estimate and prescription.

Read the kidney measure before the cutoff

These units and methods are not automatically interchangeable. NIDDK's drug-dosing guidance explains that labels have used several different methods. It also discusses a combined creatinine-cystatin C estimate when the result is near a dosing cutoff and a more accurate assessment could change the decision.

For unusual body size, clinicians may convert an indexed result using eGFR in mL/min = indexed eGFR × body surface area / 1.73. This does not turn it into Cockcroft-Gault CrCl. The creatinine clearance comparison explains that separate distinction.

Metformin: FDA thresholds, not a self-dosing schedule

The FDA-approved GLUMETZA (metformin extended-release) label, revised August 2026 states:

• Obtain eGFR before starting metformin.
• Metformin is contraindicated when eGFR is below 30.
• Starting metformin with eGFR 30–45 is not recommended.
• If eGFR later falls below 45 during treatment, assess the benefits and risks of continuing; discontinue below 30 under clinical direction.
• Monitor kidney function at least annually, and more often when risk of impairment is greater.

These are renal thresholds from this FDA-approved product label, not a universal dose table. A result of 50 does not guarantee that a particular dose is safe during dehydration, acute illness, or other contraindications. Product labeling and local guidance may differ. For iodinated contrast procedures, this label gives additional temporary-hold and reassessment instructions for specified groups; ask the treating team rather than applying a rule to every scan.

Gabapentin: the label uses creatinine clearance

The DailyMed gabapentin label bases its renal adjustment table on CrCl in mL/min, not CKD stages or indexed eGFR bands. It also includes dialysis considerations. A total daily dose and its dosing interval cannot be selected from “G3a” or “G3b” alone.

Gabapentin can accumulate when clearance is reduced. New sedation, dizziness, or imbalance deserves review, but do not abruptly change a prescription without a clinician's plan.

A medication review that answers useful questions

Bring the latest and previous kidney reports and a complete list of prescriptions, non-prescription pain medicines, vitamins, and herbal products. For each drug, ask:

1. Which kidney measure and unit does this label require?
2. Is the current kidney function stable enough for the estimating equation?
3. Does the indication or formulation change the instructions?
4. Does the dose, interval, or monitoring plan need adjustment?
5. Is there a temporary illness or procedure plan, and who should be contacted?

Some kidney-protective drugs can cause an initial eGFR reduction, but a large or unexpected change still needs assessment. Do not assume every decrease is protective or harmless. Read the sudden-drop guide if the change is new.

An online estimate can support a conversation; it cannot safely replace drug labeling, clinical examination, or pharmacist review.